IBDEI04G ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5658,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,5659,0)
 ;;=200.20^^48^426^102
 ;;^UTILITY(U,$J,358.3,5659,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5659,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,5659,1,5,0)
 ;;=5^Lymphoma,Burkett's,Unspecified Sites
 ;;^UTILITY(U,$J,358.3,5659,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,5660,0)
 ;;=202.00^^48^426^104
 ;;^UTILITY(U,$J,358.3,5660,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5660,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,5660,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,5660,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,5661,0)
 ;;=200.10^^48^426^103
 ;;^UTILITY(U,$J,358.3,5661,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5661,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,5661,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,5661,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,5662,0)
 ;;=273.3^^48^426^105
 ;;^UTILITY(U,$J,358.3,5662,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5662,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,5662,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,5662,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,5663,0)
 ;;=203.00^^48^426^115
 ;;^UTILITY(U,$J,358.3,5663,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5663,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,5663,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,5663,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,5664,0)
 ;;=203.01^^48^426^114
 ;;^UTILITY(U,$J,358.3,5664,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5664,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,5664,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,5664,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,5665,0)
 ;;=238.6^^48^426^118
 ;;^UTILITY(U,$J,358.3,5665,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5665,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,5665,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,5665,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,5666,0)
 ;;=205.00^^48^426^19
 ;;^UTILITY(U,$J,358.3,5666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5666,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,5666,1,5,0)
 ;;=5^Aml, W/O Remission
 ;;^UTILITY(U,$J,358.3,5666,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,5667,0)
 ;;=205.01^^48^426^18
 ;;^UTILITY(U,$J,358.3,5667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5667,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,5667,1,5,0)
 ;;=5^Aml, In Remission
 ;;^UTILITY(U,$J,358.3,5667,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,5668,0)
 ;;=205.10^^48^426^63
 ;;^UTILITY(U,$J,358.3,5668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5668,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,5668,1,5,0)
 ;;=5^Cml, W/O Remission
 ;;^UTILITY(U,$J,358.3,5668,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,5669,0)
 ;;=205.11^^48^426^62
 ;;^UTILITY(U,$J,358.3,5669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5669,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,5669,1,5,0)
 ;;=5^Cml, In Remission
 ;;^UTILITY(U,$J,358.3,5669,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,5670,0)
 ;;=289.0^^48^426^65
 ;;^UTILITY(U,$J,358.3,5670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5670,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,5670,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,5670,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,5671,0)
 ;;=238.4^^48^426^119
 ;;^UTILITY(U,$J,358.3,5671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5671,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,5671,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,5671,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,5672,0)
 ;;=V58.61^^48^426^144
 ;;^UTILITY(U,$J,358.3,5672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5672,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,5672,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,5672,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,5673,0)
 ;;=282.49^^48^426^134
 ;;^UTILITY(U,$J,358.3,5673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5673,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,5673,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,5673,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,5674,0)
 ;;=289.89^^48^426^29
 ;;^UTILITY(U,$J,358.3,5674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5674,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,5674,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,5674,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,5675,0)
 ;;=238.79^^48^426^100
 ;;^UTILITY(U,$J,358.3,5675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5675,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,5675,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis Nec
 ;;^UTILITY(U,$J,358.3,5675,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,5676,0)
 ;;=287.30^^48^426^120
 ;;^UTILITY(U,$J,358.3,5676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5676,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,5676,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,5676,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,5677,0)
 ;;=288.09^^48^426^15
 ;;^UTILITY(U,$J,358.3,5677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5677,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,5677,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,5677,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,5678,0)
 ;;=284.81^^48^426^26
 ;;^UTILITY(U,$J,358.3,5678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5678,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,5678,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,5678,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,5679,0)
 ;;=284.89^^48^426^25
 ;;^UTILITY(U,$J,358.3,5679,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5679,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,5679,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,5679,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,5680,0)
 ;;=284.9^^48^426^23
 ;;^UTILITY(U,$J,358.3,5680,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5680,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,5680,1,5,0)
 ;;=5^Aplastic Anemia NOS
 ;;^UTILITY(U,$J,358.3,5680,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,5681,0)
 ;;=289.84^^48^426^136
 ;;^UTILITY(U,$J,358.3,5681,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5681,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,5681,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,5681,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,5682,0)
 ;;=204.02^^48^426^12
 ;;^UTILITY(U,$J,358.3,5682,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5682,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,5682,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,5682,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,5683,0)
 ;;=204.12^^48^426^35
 ;;^UTILITY(U,$J,358.3,5683,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5683,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,5683,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,5683,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,5684,0)
 ;;=204.21^^48^426^129
 ;;^UTILITY(U,$J,358.3,5684,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5684,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,5684,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,5684,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,5685,0)
 ;;=204.20^^48^426^130
 ;;^UTILITY(U,$J,358.3,5685,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5685,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,5685,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,5685,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,5686,0)
 ;;=204.22^^48^426^131
 ;;^UTILITY(U,$J,358.3,5686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5686,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,5686,1,5,0)
 ;;=5^Subacute LL, in Relapse
 ;;^UTILITY(U,$J,358.3,5686,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,5687,0)
 ;;=203.02^^48^426^116
 ;;^UTILITY(U,$J,358.3,5687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5687,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,5687,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,5687,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,5688,0)
 ;;=205.02^^48^426^13
 ;;^UTILITY(U,$J,358.3,5688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5688,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,5688,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,5688,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,5689,0)
 ;;=205.12^^48^426^36
 ;;^UTILITY(U,$J,358.3,5689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5689,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,5689,1,5,0)
 ;;=5^CML, In Relapse
 ;;^UTILITY(U,$J,358.3,5689,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,5690,0)
 ;;=V10.91^^48^426^76
 ;;^UTILITY(U,$J,358.3,5690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5690,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,5690,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,5690,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,5691,0)
 ;;=V10.91^^48^426^86
 ;;^UTILITY(U,$J,358.3,5691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5691,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,5691,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,5691,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,5692,0)
 ;;=465.9^^48^427^73
 ;;^UTILITY(U,$J,358.3,5692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5692,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,5692,1,5,0)
 ;;=5^Uri
 ;;^UTILITY(U,$J,358.3,5692,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,5693,0)
 ;;=462.^^48^427^60
 ;;^UTILITY(U,$J,358.3,5693,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5693,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,5693,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,5693,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,5694,0)
 ;;=466.0^^48^427^3
 ;;^UTILITY(U,$J,358.3,5694,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5694,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,5694,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,5694,2)
 ;;=^259084
 ;;^UTILITY(U,$J,358.3,5695,0)
 ;;=112.1^^48^427^78
 ;;^UTILITY(U,$J,358.3,5695,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5695,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,5695,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
 ;;^UTILITY(U,$J,358.3,5695,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,5696,0)
 ;;=616.0^^48^427^13
 ;;^UTILITY(U,$J,358.3,5696,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5696,1,4,0)
 ;;=4^616.0
 ;;^UTILITY(U,$J,358.3,5696,1,5,0)
 ;;=5^Cervicitis
